Navigation Links
Ground-breaking new insight into the development of Alzheimer's disease
Date:4/22/2008

Leuven, Belgium C According to estimates there are 85,000 Alzheimer patients in our country and approximately 20,000 new cases every year. This spectacular increase is due to the increasing ageing population. Unfortunately it is still unclear precisely which ageing process forms the basis of this spectacular rise in the occurrence of the disease. VIB scientists affiliated to K.U.Leuven have discovered an important molecular link between Alzheimer's disease and the development of the typical plaques in the brains of Alzheimer patients. This discovery is an important breakthrough in the fundamental research into the cause of Alzheimer's disease.

Alzheimer's disease: a growing problem

Alzheimer's disease, a neurodegenerative disease that slowly and gradually destroys brain cells, is the most common form of dementia in the Western world. The way in which it affects the memory and mental functioning makes it one of the most frightening disorders. Over the last 15 years the amount of research worldwide into this still incurable disease has grown considerably: faster diagnosis of the disease and better treatment are essential!

Amyloid plaques and Alzheimer's disease

Alzheimer's disease is associated with amyloid plaques C i.e. abnormal accumulations of protein fragments C that form in the brain cells. A few years ago Bart De Strooper and other researchers unravelled the process by which these plaques develop in the familial form of Alzheimer's disease (less common form). -secretase, which cuts proteins at a specific location C plays an important role here. Sometimes the secretase cuts in the wrong place, which results in a by-product and thus the formation of plaques. In the most common form of the disorder the same sort of plaques are found, but there is still little known about their development mechanism.

BACE1 or A-secretase

In patients with the most common form of Alzheimer's disease the brain
'/>"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
2. On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects
3. Design-her Gals(TM) Announces the Ground-Breaking Virtual On-Line Walk for Wishes to Grant Dreams for Stage IV Breast Cancer Patients this Holiday Season Through Gal to Gal Foundation
4. John Hancocks EZ Route Post-Enrollment Education Program Wins 2008 Insight Award for Customer Advocacy in Financial Services
5. New studies add insights to infant feeding and obesity issue
6. Forecasting MDs prescriptions choice? Ask their patients, says Management Insights study
7. Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008
8. Shannon Brownlee, Author of Overtreated, to Keynote at Defined Healths 8th Annual Therapeutic Insight Conference
9. Insights on Paying for Boomers Care Needs in 20-40 Years Helped by New Report
10. 10th Annual Human Resources Conference, June 4-6: Sharing New Insights on Workforce Planning
11. Key factor in brain development revealed, offers insight into disorder
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Nurses Report Quality Health Benefits Key to Choosing an Employer 2Health News:Pilot Program Successfully Addresses Mental Health Issues in Pennsylvania's Children 2Health News:First Patients Treated in Italy With the Percutaneous MitraClip(R) System 2Health News:First Patients Treated in Italy With the Percutaneous MitraClip(R) System 3Health News:Become Mariah Carey's Personal Fashion Designer! 2Health News:Become Mariah Carey's Personal Fashion Designer! 3Health News:Become Mariah Carey's Personal Fashion Designer! 4Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 2Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 3Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 4Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 5Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 6Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 7
Breaking Medicine Technology:Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2CryoLife Provides Initial 2010 Financial Guidance 6633 1CryoLife Provides Initial 2010 Financial Guidance 6633 2CryoLife Provides Initial 2010 Financial Guidance 6633 3CryoLife Provides Initial 2010 Financial Guidance 6633 4CryoLife Provides Initial 2010 Financial Guidance 6633 5MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 6627 1Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 6627 2